Literature DB >> 15727743

Primary HIV-1 Infection: Diagnosis, Pathogenesis, and Treatment.

Malini Soogoor1, Eric S Daar.   

Abstract

Primary HIV-1 infection represents the time when the virus is first disseminating throughout the body and induces host immune responses. Diagnosing this stage of disease requires an understanding of who is at risk, the clinical manifestations of primary infection, and how the diagnosis is made. Identifying these individuals allows for counseling to prevent further transmission to others and the potential benefits associated with early antiretroviral therapy. Moreover, studying these individuals provides important insight into the biology of HIV-1 transmission and immunopathogenesis.

Entities:  

Year:  2005        PMID: 15727743     DOI: 10.1007/s11908-005-0075-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  48 in total

1.  Lipodystrophy following antiretroviral therapy of primary HIV infection.

Authors:  J Miller; A Carr; D Smith; S Emery; M G Law; P Grey; D A Cooper
Journal:  AIDS       Date:  2000-10-20       Impact factor: 4.177

2.  Predicting the transmission of drug-resistant HIV: comparing theory with data.

Authors:  Sally M Blower; A Nick Aschenbach; Jim O Kahn
Journal:  Lancet Infect Dis       Date:  2003-01       Impact factor: 25.071

3.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

4.  Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.

Authors:  D N Forthal; G Landucci; E S Daar
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Use of laboratory tests and clinical symptoms for identification of primary HIV infection.

Authors:  Frederick M Hecht; Michael P Busch; Bhupat Rawal; Marcy Webb; Eric Rosenberg; Melinda Swanson; Margaret Chesney; Jennifer Anderson; Jay Levy; James O Kahn
Journal:  AIDS       Date:  2002-05-24       Impact factor: 4.177

6.  A controlled trial of zidovudine in primary human immunodeficiency virus infection.

Authors:  S Kinloch-De Loës; B J Hirschel; B Hoen; D A Cooper; B Tindall; A Carr; J H Saurat; N Clumeck; A Lazzarin; L Mathiesen
Journal:  N Engl J Med       Date:  1995-08-17       Impact factor: 91.245

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Persistence of primary drug resistance among recently HIV-1 infected adults.

Authors:  Jason D Barbour; Frederick M Hecht; Terri Wrin; Teri J Liegler; Clarissa A Ramstead; Michael P Busch; Mark R Segal; Christos J Petropoulos; Robert M Grant
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

9.  Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less-sensitive test strategy.

Authors:  Niel T Constantine; Anne M Sill; Noreen Jack; Kristen Kreisel; Jeffrey Edwards; Thomas Cafarella; Harry Smith; Courtenay Bartholomew; Farley R Cleghorn; William A Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2003-01-01       Impact factor: 3.731

10.  Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort.

Authors:  V Schiffer; C Deveau; L Meyer; I Iraqui; A Nguyen-Wartel; M-L Chaix; J-F Delfraissy; C Rouzioux; A Venet; C Goujard
Journal:  HIV Med       Date:  2004-09       Impact factor: 3.180

View more
  1 in total

1.  Clinical and immunological status of a newly diagnosed HIV positive population, in Marrakech, Morocco.

Authors:  B Admou; E Elharti; H Oumzil; A Addebbous; M Amine; K Zahlane; N Soraa; L Zougaghi; K Haouach; N Tassi; L Aajly; L Chabaa; R El Aouad
Journal:  Afr Health Sci       Date:  2010-12       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.